公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
2024 | Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib | Wu, Jia-Jun; Tseng, Jeng-Sen; Zheng, Zhe-Rong; Chu, Cheng-Hsiang; Chen, Kun-Chieh; MONG-WEI LIN ; Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; JIN-SHING CHEN ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 0 | | |
2021 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients | Hsu, Kuo-Hsuan; Huang, Jing-Wen; Tseng, Jeng-Sen; Chen, Kuan-Wen; Weng, Yih-Chyang; SUNG-LIANG YU ; Yang, Tsung-Ying; Huang, Yen-Hsiang; Chen, Jeremy J W; Chen, Kun-Chieh; Chang, Gee-Chen | OncoTargets and therapy | 7 | 6 | |
2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
2014 | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; CHONG-JEN YU ; WEI-YU LIAO ; Tsai, Chi-Ren; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy Jw; Chen, Hsuan-Yu; MONG-HSUN TSAI | OncoTargets and Therapy | 15 | 14 | |
2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |
2021 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study | Huang, Yen-Hsiang; Hung, Jen-Yu; Ko, How-Wen; Su, Po-Lan; Lai, Chun-Liang; Chang, Huang-Chih; Hsia, Te-Chun; Lin, Sheng-Hao; Wu, Kuan-Li; Yang, Cheng-Ta; Su, Wu-Chou; Chu, Yi-Chun; Wang, Chin-Chou; WEI-YU LIAO ; YEN-TING LIN ; Lin, Ching-Hsiung; Lin, Meng-Chih; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Lee, Mei-Hsuan; SUNG-LIANG YU ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 3 | 2 | |
2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |